Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)

We report a case of a patient with erythema multiforme major following COVID-19 (coronavirus disease 2019) vaccination. Lesions on skin and mucous membranes developed 48 h after the second dose of the mRNA-vaccine BNT162b2 (Tozinameran, Comirnaty®). Under the application of external glucocorticoids...

Descripción completa

Detalles Bibliográficos
Autores principales: Wunderlich, K., Dirschka, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Kasuistiken
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530369/
https://www.ncbi.nlm.nih.gov/pubmed/34676438
http://dx.doi.org/10.1007/s00105-021-04911-4
_version_ 1784586658344075264
author Wunderlich, K.
Dirschka, T.
author_facet Wunderlich, K.
Dirschka, T.
author_sort Wunderlich, K.
collection PubMed
description We report a case of a patient with erythema multiforme major following COVID-19 (coronavirus disease 2019) vaccination. Lesions on skin and mucous membranes developed 48 h after the second dose of the mRNA-vaccine BNT162b2 (Tozinameran, Comirnaty®). Under the application of external glucocorticoids complete resolution was achieved within 3 weeks.
format Online
Article
Text
id pubmed-8530369
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-85303692021-10-22 Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2) Wunderlich, K. Dirschka, T. Hautarzt Kasuistiken We report a case of a patient with erythema multiforme major following COVID-19 (coronavirus disease 2019) vaccination. Lesions on skin and mucous membranes developed 48 h after the second dose of the mRNA-vaccine BNT162b2 (Tozinameran, Comirnaty®). Under the application of external glucocorticoids complete resolution was achieved within 3 weeks. Springer Medizin 2021-10-21 2022 /pmc/articles/PMC8530369/ /pubmed/34676438 http://dx.doi.org/10.1007/s00105-021-04911-4 Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Kasuistiken
Wunderlich, K.
Dirschka, T.
Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)
title Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)
title_full Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)
title_fullStr Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)
title_full_unstemmed Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)
title_short Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2)
title_sort erythema exsudativum multiforme infolge einer covid-19-impfung (bnt162b2)
topic Kasuistiken
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530369/
https://www.ncbi.nlm.nih.gov/pubmed/34676438
http://dx.doi.org/10.1007/s00105-021-04911-4
work_keys_str_mv AT wunderlichk erythemaexsudativummultiformeinfolgeeinercovid19impfungbnt162b2
AT dirschkat erythemaexsudativummultiformeinfolgeeinercovid19impfungbnt162b2

Ejemplares similares